Advertisement

Ovarian and Tubal Cancer

  • Görker Sel
Chapter

Abstract

Which cancer has the highest mortality of all gynecologic malignancies?

Suggested Reading

  1. 1.
    DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG. Epithelial ovarian cancer. In: Clinical gynecologic oncology. 9th ed. Philadelphia: Elsevier Health Sciences; 2018. p. 253–90.Google Scholar
  2. 2.
    DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG. Germ cell, stromal, and other ovarian tumors. In: Clinical gynecologic oncology, vol. 2018. 9th ed. Philadelphia: Elsevier Health Sciences. p. 290–314.CrossRefGoogle Scholar
  3. 3.
    DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG. Fallopian tube cancer. In: Clinical gynecologic oncology, vol. 2018. 9th ed. Philadelphia: Elsevier Health Sciences. p. 314–20.Google Scholar
  4. 4.
    Chen L-M, Berek JS. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors. UpToDate (27 Nov 2018). https://www.uptodate.com/contents/epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-epidemiology-and-risk-factors.
  5. 5.
    Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119(Suppl 2):S118.CrossRefGoogle Scholar
  6. 6.
    Muto MG. Approach to the patient with an adnexal mass. UpToDate (23 Feb 2018). https://www.uptodate.com/contents/approach-to-the-patient-with-an-adnexal-mass.
  7. 7.
    Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–90.CrossRefGoogle Scholar
  8. 8.
    Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131(5):909–27.CrossRefGoogle Scholar
  9. 9.
    Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16.CrossRefGoogle Scholar
  10. 10.
    Açıkgöz RB, Harma M. Pelvik Kitlelerin Malignite Riski Değerlendirilmesinde Kanser Antijeni 125 (Ca 125), Human Epididymis Protein 4 (HE4), Soluble Mezotelin Related Protein (SMRP) veFolat Reseptör Alfa (FOLRα) Ölçümünün Yeri. Med J Western Black Sea. 2018;2(3):208–16.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Görker Sel
    • 1
  1. 1.Faculty of Medicine, Department of Obstetrics and GynecologyZonguldak Bülent Ecevit UniversityZonguldakTurkey

Personalised recommendations